These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15050189)

  • 1. Risk assessment and strategies to achieve lipid goals: lessons from real-world clinical practice.
    Schuster H
    Am J Med; 2004 Mar; 116 Suppl 6A():26S-30S. PubMed ID: 15050189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' attitudes toward detection of heterozygous familial hypercholesterolemia.
    Andersen LK; Jensen HK; Juul S; Faergeman O
    Arch Intern Med; 1997 Mar; 157(5):553-60. PubMed ID: 9066460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia.
    Sachais BS; Katz J; Ross J; Rader DJ
    J Clin Apher; 2005 Dec; 20(4):252-5. PubMed ID: 15880364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of natural menopause on postprandial lipemia in heterozygotes for familial hypercholesterolemia.
    Kolovou GD; Anagnostopoulou KK; Pilatis ND; Giannopoulou M; Hoursalas IS; Pavlidis AN; Adamopoulou E; Valaora AI; Mikhailidis DP; Cokkinos DV
    J Womens Health (Larchmt); 2004 Dec; 13(10):1119-26. PubMed ID: 15650345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lipid metabolism disorders--diagnosis and therapy in general practice. 1: Hypercholesterolemia].
    Richter WO
    Fortschr Med; 1996 Apr; 114(11):133-4. PubMed ID: 8682426
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia.
    Skoumas I; Masoura C; Pitsavos C; Tousoulis D; Papadimitriou L; Aznaouridis K; Chrysohoou C; Giotsas N; Toutouza M; Tentolouris C; Antoniades C; Stefanadis C
    Int J Cardiol; 2007 Oct; 121(2):178-83. PubMed ID: 17188767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
    Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D
    Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
    Woloshin S; Schwartz LM; Kerin K; Welch HG
    J Gen Intern Med; 2007 Feb; 22(2):197-204. PubMed ID: 17356986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation.
    Civeira F; Castillo S; Alonso R; Meriño-Ibarra E; Cenarro A; Artied M; Martín-Fuentes P; Ros E; Pocoví M; Mata P;
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1960-5. PubMed ID: 16020744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.
    Bianchi C; Montalvo V; Ou HW; Bishop V; Abou-Zamzam AM
    Ann Vasc Surg; 2007 Mar; 21(2):163-6. PubMed ID: 17349357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterozygote men with familial hypercholesterolaemia may have an abnormal triglyceride response post-prandially. Evidence for another predictor of vascular risk in familial hypercholesterolaemia.
    Kolovou GD; Anagnostopoulou KK; Pilatis ND; Iraklianou S; Hoursalas IS; Liberi S; Pavlidis AN; Dritsas A; Mikhailidis DP; Cokkinos DV
    Int J Clin Pract; 2005 Mar; 59(3):311-7. PubMed ID: 15857328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk.
    Ramos R; Quesada M; Solanas P; Subirana I; Sala J; Vila J; Masiá R; Cerezo C; Elosua R; Grau M; Cordón F; Juvinyà D; Fitó M; Isabel Covas M; Clarà A; Angel Muñoz M; Marrugat J;
    Eur J Vasc Endovasc Surg; 2009 Sep; 38(3):305-11. PubMed ID: 19515589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of peripheral arterial occlusive disease with major coronary events in a mediterranean population with low coronary heart disease incidence.
    Merino J; Planas A; De Moner A; Gasol A; Contreras C; Marrugat J; Vidal-Barraquer F; Clarà A
    Eur J Vasc Endovasc Surg; 2008 Jul; 36(1):71-6. PubMed ID: 18396072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia.
    van der Net JB; Janssens AC; Defesche JC; Kastelein JJ; Sijbrands EJ; Steyerberg EW
    Am J Cardiol; 2009 Feb; 103(3):375-80. PubMed ID: 19166692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of borderline peripheral arterial disease to cardiovascular disease risk.
    Menke A; Muntner P; Wildman RP; Dreisbach AW; Raggi P
    Am J Cardiol; 2006 Nov; 98(9):1226-30. PubMed ID: 17056334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors.
    Krobot KJ; Yin DD; Alemao E; Steinhagen-Thiessen E
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):37-45. PubMed ID: 15703504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge produced by familial homozygous hypercholesterolemia when treating premature coronary arterial disease in the young.
    Shankarappa RK; Moorthy N; Bhat SP; Dwarakaprasad R; Nanjappa MC
    Cardiol Young; 2009 Jun; 19(3):257-63. PubMed ID: 19344536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview.
    Hutter CM; Austin MA; Humphries SE
    Am J Epidemiol; 2004 Sep; 160(5):430-5. PubMed ID: 15321839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.